Ratings for TScan Therapeutics (NASDAQ:TCRX) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of ...
15don MSN
Strong analyst sentiment on TScan Therapeutics (TCRX) amid ongoing momentum in cell therapy space
TScan Therapeutics, Inc. (NASDAQ:TCRX) is among the top 10 stocks under $5 that could triple. As of March 19, 2026, analysts ...
TScan Therapeutics secures a $52.5 million term loan from Silicon Valley Bank to enhance financial flexibility and support cancer therapies. TScan Therapeutics, Inc. has announced a term loan facility ...
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) ...
A dose bottle of the medication is in the medical tech's hand As of March 19, 2026, analysts maintain a strong sentiment regarding TScan Therapeutics, Inc. (TCRX). With over 80% of analysts holding a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results